Compare IRON & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | BHC |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 2020 | 1996 |
| Metric | IRON | BHC |
|---|---|---|
| Price | $66.38 | $5.92 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 3 |
| Target Price | ★ $99.54 | $8.33 |
| AVG Volume (30 Days) | 943.0K | ★ 1.9M |
| Earning Date | 05-29-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 423.08 |
| EPS | N/A | ★ 0.42 |
| Revenue | N/A | ★ $8,724,000,000.00 |
| Revenue This Year | N/A | $4.24 |
| Revenue Next Year | $215.03 | N/A |
| P/E Ratio | ★ N/A | $14.08 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.82 | $4.28 |
| 52 Week High | $99.50 | $8.69 |
| Indicator | IRON | BHC |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 43.74 |
| Support Level | $57.45 | $5.89 |
| Resistance Level | $82.70 | $6.32 |
| Average True Range (ATR) | 6.10 | 0.30 |
| MACD | 0.27 | 0.04 |
| Stochastic Oscillator | 73.52 | 50.00 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.